Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Hepatol Res. 2014 Oct 7;45(7):794–803. doi: 10.1111/hepr.12411

Figure 4. Inhibition of the CXCR4/CXCL12 chemokine axis with once weekly injections of AMD3100 in the chronic CCl4 model has no effect on hepatic fibrosis and inflammation.

Figure 4

Mice received 4 weeks of CCl4 with once weekly injections of AMD3100. Administration of AMD3100 did not lead to any differences in the degree of fibrosis by Sirius red staining (A) quantified by morphometric analysis (B) or hepatic inflammation (C). Representative images shown, n=5.